Patent ID: 9714280
Date: 2017-07-25
CPC Classifications: A01K,A61K,A61P,C07K,C12N,G01N

Claim:
1. A genetically modified mammalian cell that has reduced immunogenicity and/or improved immunosuppression as compared to the mammalian cell without said genetic modification, wherein the genetically modified mammalian cell comprises in its genome an exogenous nucleic acid comprising: (a) a nucleic acid sequence encoding a Human leukocyte antigen-G (HLA-G) protein comprising a full length amino acid sequence of SEQ ID NO:2 operably linked to an Elongation Factor-1 alpha (EF-1α) promoter comprising the sequence of SEQ ID NO:6; and (b) a 3′ untranslated region (UTR) comprising a full length nucleotide sequence of SEQ ID NO:3; wherein the genetically modified mammalian cell is selected from the group consisting of embryonic stem cell, embryonic epidermal progenitors and human dermal fibroblast cells, and wherein the encoded HLA-G protein is expressed by the genetically modified mammalian cell for at least seven weeks.